The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Activation of Matrix Metalloproteinase-9 (MMP-9) via a Converging Plasmin/Stromelysin-1 Cascade Enhances Tumor Cell Invasion
Open accessAbstract
Matrix metalloproteinase-9 (MMP-9) may play a critical catalytic role in tissue remodeling in vivo, but it is secreted by cells as a stable, inactive zymogen, pro-MMP-9, and requires activation for catalytic function. A number of proteolytic enzymes activate pro-MMP-9 in vitro, but the natural activator(s) of MMP-9 is unknown. To examine MMP-9 activation in a cellular setting we employed cultures of human tumor cells (MDA-MB-231 breast carcinoma cells) that were induced to produce MMP-9 over a 200-fold concentration range (0.03-8.1 nM). The levels of tissue inhibitors of metalloproteinase (TIMPs) in the induced cultures remain relatively constant at 1-4 nM. Quantitation of the zymogen/active enzyme status of MMP-9 in the MDA-MB-231 cultures indicates that even in the presence of potential activators, the molar ratio of endogenous MMP-9 to TIMP dictates whether pro-MMP-9 activation can progress. When the MMP-9/TIMP ratio exceeds 1.0, MMP-9 activation progresses, but through an interacting protease cascade involving plasmin and stromelysin 1 (MMP-3). Plasmin, generated by the endogenous urokinase-type plasminogen activator, is not an efficient activator of pro-MMP-9, neither the secreted pro-MMP-9 nor the very low levels of pro-MMP-9 associated with intact cells. Although plasmin can proteolytically process pro-MMP-9, this limited action does not yield an enzymatically active MMP-9, nor does it cause the MMP-9 to be more susceptible to activation. Plasmin, however, is very efficient at generating active MMP-3 (stromelysin-1) from exogenously added pro-MMP-3. The activated MMP-3 becomes a potent activator of the 92-kDa pro-MMP-9, yielding an 82-kDa species that is enzymatically active in solution and represents up to 50-75% conversion of the zymogen. The activated MMP-9 enhances the invasive phenotype of the cultured cells as their ability to both degrade extracellular matrix and transverse basement membrane is significantly increased following zymogen activation. That this enhanced tissue remodelling capability is due to the activation of MMP-9 is demonstrated through the use of a specific anti-MMP-9 blocking monoclonal antibody.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matrix metalloproteinases and their inhibitors in connective tissue remodeling
Woessner, J. F. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.8.1850705 · Cited by 3,282
Matrix Metalloproteinases: A Review
Birkedal-Hansen, H., Moore, W. G. I., Bodden, M. K., Windsor, L. J., Birkedal-Hansen, B., DeCarlo, A., & Engler, J. A. (1993) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/10454411930040020401 · Cited by 2,970
A matrix metalloproteinase expressed on the surface of invasive tumour cells
Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., & Seiki, M. (1994) · Nature · doi:10.1038/370061a0 · Cited by 2,551
Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase
Strongin, A. Y., Collier, I., Bannikov, G., Marmer, B. L., Grant, G. A., & Goldberg, G. I. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.10.5331 · Cited by 1,593
Tumor Cell Interactions with the Extracellular Matrix During Invasion and Metastasis
Stetler-Stevenson, W. G., Aznavoorian, S., & Liotta, L. A. (1993) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.09.110193.002545 · Cited by 1,526
The matrix‐degrading metalloproteinases
Matrisian, L. M. (1992) · BioEssays · doi:10.1002/bies.950140705 · Cited by 1,364
Biology and biochemistry of proteinases in tumor invasion
Mignatti, P., & Rifkin, D. B. (1993) · Physiological Reviews · doi:10.1152/physrev.1993.73.1.161 · Cited by 1,244
Wilhelm, S. M., Collier, I. E., Marmer, B. L., Eisen, A. Z., Grant, G. A., & Goldberg, G. I. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)71480-4 · Cited by 1,109
Matrix Metalloproteinase-2 Is an Interstitial Collagenase
Aimes, R. T., & Quigley, J. P. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.11.5872 · Cited by 944
Self-citation92-kD type IV collagenase mediates invasion of human cytotrophoblasts.
Librach, C. L., Werb, Z., Fitzgerald, M. L., Chiu, K., Corwin, N. M., Esteves, R. A., Grobelny, D., Galardy, R., Damsky, C. H., & Fisher, S. J. (1991) · The Journal of cell biology · doi:10.1083/jcb.113.2.437 · Cited by 720
Cited by
Matrix metalloproteinases and angiogenesis
Rundhaug, J. E. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00355.x · Cited by 960
Lee, C. G., Homer, R. J., Zhu, Z., Lanone, S., Wang, X., Koteliansky, V., Shipley, J. M., Gotwals, P., Noble, P., Chen, Q., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.809 · Cited by 940
Matrix metalloproteinases in neuroinflammation
Rosenberg, G. A. (2002) · Glia · doi:10.1002/glia.10108 · Cited by 868
Gelatinase-mediated migration and invasion of cancer cells
Björklund, M., & Koivunen, E. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.03.001 · Cited by 661
Control of matrix metalloproteinase catalytic activity
Ra, H.-J., & Parks, W. C. (2007) · Matrix Biology · doi:10.1016/j.matbio.2007.07.001 · Cited by 647
Matrix Metalloproteinase-9: Many Shades of Function in Cardiovascular Disease
Yabluchanskiy, A., Ma, Y., Iyer, R. P., Hall, M. E., & Lindsey, M. L. (2013) · Physiology · doi:10.1152/physiol.00029.2013 · Cited by 635
Ardi, V. C., Kupriyanova, T. A., Deryugina, E. I., & Quigley, J. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706438104 · Cited by 602
Self-citationSabeh, F., Ota, I., Holmbeck, K., Birkedal-Hansen, H., Soloway, P., Balbin, M., Lopez-Otin, C., Shapiro, S., Inada, M., Krane, S., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200408028 · Cited by 586
Unraveling the role of proteases in cancer
Koblinski, J. E., Ahram, M., & Sloane, B. F. (2000) · Clinica Chimica Acta · doi:10.1016/s0009-8981(99)00224-7 · Cited by 580
Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview
Mondal, S., Adhikari, N., Banerjee, S., Amin, S. A., & Jha, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112260 · Cited by 556
Montaner, J., Molina, C. A., Monasterio, J., Abilleira, S., Arenillas, J. F., Ribó, M., Quintana, M., & Alvarez-Sabín, J. (2003) · Circulation · doi:10.1161/01.cir.0000046451.38849.90 · Cited by 555
Proteolytic networks in cancer
Mason, S. D., & Joyce, J. A. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.12.002 · Cited by 552
Chitinase-3 like-protein-1 function and its role in diseases
Zhao, T., Su, Z., Li, Y., Zhang, X., & You, Q. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00303-7 · Cited by 536
Curran, S., & Murray, G. I. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00156-8 · Cited by 531
Matrix Metalloproteinase-Induced Epithelial-Mesenchymal Transition in Breast Cancer
Radisky, E. S., & Radisky, D. C. (2010) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-010-9177-x · Cited by 524
Hemmann, S., Graf, J., Roderfeld, M., & Roeb, E. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.02.003 · Cited by 509
Rodríguez-Manzaneque, J. C., Lane, T. F., Ortega, M. A., Hynes, R. O., Lawler, J., & Iruela-Arispe, M. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171460498 · Cited by 473
Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice
Gough, P. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25074 · Cited by 452
Type II Transmembrane Serine Proteases
Bugge, T. H., Antalis, T. M., & Wu, Q. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.021006 · Cited by 449
Li, Y. (2000) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00003-1 · Cited by 434
Chotikavanich, S., de Paiva, C. S., Li, D. Q., Chen, J. J., Bian, F., Farley, W. J., & Pflugfelder, S. C. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2476 · Cited by 402
TIMP-2 Is Required for Efficient Activation of proMMP-2 in Vivo
Wang, Z., Juttermann, R., & Soloway, P. D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001270200 · Cited by 390
Rosenberg, G. A., Cunningham, L. A., Wallace, J., Alexander, S., Estrada, E. Y., Grossetete, M., Razhagi, A., Miller, K., & Gearing, A. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03294-7 · Cited by 388
Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo
Ling, Q., Jacovina, A. T., Deora, A., Febbraio, M., Simantov, R., Silverstein, R. L., Hempstead, B., Mark, W. H., & Hajjar, K. A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19684 · Cited by 381
Type II Transmembrane Serine Proteases
Hooper, J. D., Clements, J. A., Quigley, J. P., & Antalis, T. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r000020200 · Cited by 357
Self-citationInflammatory macrophage migration requires MMP-9 activation by plasminogen in mice
Gong, Y., Hart, E., Shchurin, A., & Hoover-Plow, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32750 · Cited by 334
Clapper, J. R., Hendricks, M. D., Gu, G., Wittmer, C., Dolman, C. S., Herich, J., Athanacio, J., Villescaz, C., Ghosh, S. S., Heilig, J. S., et al. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00079.2013 · Cited by 294
“In addition to its fibrinolytic activity, plasmin degrades components of the ECM such as laminin, proteoglycans, and collagens and is an activator of matrix metalloproteinases, thus potentially resulting in reduced tissue fibrosis (4, 20, 22, 25, 28).”
BackgroundPrudova, A., auf dem Keller, U., Butler, G. S., & Overall, C. M. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m000050-mcp201 · Cited by 282
Matrix metalloproteinases: roles in cancer and metastasis
Fingleton, B. (2006) · Frontiers in Bioscience · doi:10.2741/1811 · Cited by 271
Prognostic significance of MMP‐9 and TIMP‐1 serum and tissue expression in breast cancer
Wu, Z., Wu, Q., Yang, J., Wang, H., Ding, X., Yang, F., & Xu, X. (2008) · International Journal of Cancer · doi:10.1002/ijc.23337 · Cited by 268
Morini, M., Mottolese, M., Ferrari, N., Ghiorzo, F., Buglioni, S., Mortarini, R., Noonan, D. M., Natali, P. G., & Albini, A. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000801)87:3<336::aid-ijc5>3.0.co;2-3 · Cited by 267
Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis
McKleroy, W., Lee, T.-H., & Atabai, K. (2013) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00418.2012 · Cited by 261
Inaba, H., Sugita, H., Kuboniwa, M., Iwai, S., Hamada, M., Noda, T., Morisaki, I., Lamont, R. J., & Amano, A. (2014) · Cellular Microbiology · doi:10.1111/cmi.12211 · Cited by 255
Thrombospondin Type 1 Repeats Interact with Matrix Metalloproteinase 2
Bein, K., & Simons, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003834200 · Cited by 255
Hussain, B., Fang, C., & Chang, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.688090 · Cited by 255
MMP9: A Tough Target for Targeted Therapy for Cancer
Augoff, K., Hryniewicz-Jankowska, A., Tabola, R., & Stach, K. (2022) · Cancers · doi:10.3390/cancers14071847 · Cited by 255
Molecular basis of endothelial cell morphogenesis in three‐dimensional extracellular matrices
Davis, G. E., Bayless, K. J., & Mavila, A. (2002) · The Anatomical Record · doi:10.1002/ar.10159 · Cited by 253
Microglial complement receptor 3 regulates brain Aβ levels through secreted proteolytic activity
Czirr, E., Castello, N. A., Mosher, K. I., Castellano, J. M., Hinkson, I. V., Lucin, K. M., Baeza-Raja, B., Ryu, J. K., Li, L., Farina, S. N., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162011 · Cited by 126
“It can activate both plasminogen and MMPs and, therefore, mediate Aβ degradation via different pathways (Hahn-Dantona et al., 1999; Ramos-DeSimone et al., 1999).”
BackgroundWolczyk, D., Zaremba-Czogalla, M., Hryniewicz-Jankowska, A., Tabola, R., Grabowski, K., Sikorski, A. F., & Augoff, K. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0280-x · Cited by 116
A Cancer Cell Spheroid Assay to Assess Invasion in a 3D Setting
Berens, E. B., Holy, J. M., Riegel, A. T., & Wellstein, A. (2015) · Journal of Visualized Experiments · doi:10.3791/53409 · Cited by 112
Glomerular endothelial cell senescence drives age‐related kidney disease through PAI‐1
Cohen, C., Le Goff, O., Soysouvanh, F., Vasseur, F., Tanou, M., Nguyen, C., Amrouche, L., Le Guen, J., Saltel‐Fulero, O., Meunier, T., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114146 · Cited by 79
Heparanase, cell signaling, and viral infections
Koganti, R., Suryawanshi, R., & Shukla, D. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03559-y · Cited by 67
Gray, E., Thomas, T. L., Betmouni, S., Scolding, N., & Love, S. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318183d003 · Cited by 51
Kelly, E. A., Russo, A. S., Jackson, C. D., Lamantia, C. E., & Majewska, A. K. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00369 · Cited by 48
Metadata
- Authors
- Ramos-DeSimone, N., Hahn-Dantona, E., Sipley, J., Nagase, H., French, D. L., & Quigley, J. P.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1999-05
- Volume
- 274
- Issue
- 19
- Pages
- 13066-13076
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2069951758
- Cited by
- 591
- References
- 60
- FWCI
- 10.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.